| Drug Name: | Thiotepa (52-24-4) |
|---|---|
| PubChem ID: | 5453 |
| SMILES: | C1CN1P(=S)(N2CC2)N3CC3 |
| InchiKey: | FOCVUCIESVLUNU-UHFFFAOYSA-N |
| Therapeutic Category: |
| Molecular Weight (dalton) | : | 189.224 |
| LogP | : | 0.1577 |
| Ring Count | : | 0 |
| Hydrogen Bond Acceptor Count | : | 1 |
| Hydrogen Bond Donor Count | : | 0 |
| Total Polar Surface Area | : | 9.03 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Cyclophosphamide (50-18-0) | Decrease Both The Efficacy And Toxicity | Antagonistic | thiotepa was inhibit the conversion of cyclophosphamide to hydroxycyclophosphamide | Nonlinear Pharmacokinetics of Cyclophosphamide in Patients with Metastatic Breast Cancer Receiving High-Dose Chemotherapy followed by Autologous Bone Marrow Transplantation |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category